| Characteristic |
Placebo (mean ± SD) |
Erythromycin (mean ± SD) |
P value |
| Gender (M:F) |
5:9 |
13:4 |
|
| Age (years) |
9.1 ± 2.1 |
8.4 ± 2.4 |
0.15 |
| Exacerbations |
2.1 ± 2.3 |
2.2 ± 1.6 |
0.47 |
| Months on HAART |
17.0 ± 22.0 |
12.0 ± 12.8 |
0.57 |
| Weight z-score (kg) |
-1.8 ± 0.9 |
-1.6 ± 1.6 |
0.77 |
| Height z-score (cm) |
-1.7 ± 1.4 |
-1.7 ± 1.5 |
0.50 |
| BMI z-score (kg/m2) |
-0.6 ± 0.9 |
-0.5 ± 1.3 |
0.91 |
| CD4 count (%) |
22.6 ± 11.9 |
16.3 ± 6.7 |
0.01 |
| CD4 (total×106) |
881.6 ± 505.8 |
650.9 ± 446.7 |
<0.01 |
| HIV viral-load (copies/ml)* |
80.0 ± 22514.3 |
0.0 ± 9635,2 |
0.97 |
| FEV1 (% predicted) |
53.5 ± 13.6 |
56.0 ± 15.1 |
0.54 |
| FVC (% predicted) |
45.0 ± 14.3 |
49.0 ± 14.4 |
0.94 |
| FEF25/75 (% predicted) |
55.1 ± 25.3 |
56.0 ± 25.7 |
0.89 |
| IgG (g/ml) |
24.8 ± 15.4 |
26.2 ± 8.4 |
0.54 |
| CRP (mg/l) |
3.6 ± 16.1 |
9.4 ± 18.8 |
0.08 |
| Bhalla score¶ |
11.5 ± 4.3 |
15.0 ± 4.0 |
0.02 |
| Compliance (% medication) |
91.0 ± 9.9 |
92 ± 9.9 |
0.87 |
SD: Standard deviation; BMI: Body mass index; HAART: Highly active antiretroviral therapy; CD4: Cluster differentiation cell; HIV: Human immunodeficiency virus; FEV1:
Forced expiratory volume in one second; FVC: Forced vital capacity; IgG: Immunoglobulin G; CRP: C reactive protein; WCC: White cell count; ¶Bhalla score: Appendix D.
*Geometric means reported. |
